Submission for OMB review; comment request Health Information National Trends Survey 4 (HINTS 4) (NCI), 37356-37357 [2011-15994]

Download as PDF 37356 Federal Register / Vol. 76, No. 123 / Monday, June 27, 2011 / Notices within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Fax: 202– 395–7285, E-mail: OIRA_SUBMISSION@OMB.EOP.GOV, Attn: Desk Officer for the Administration for Children and Families. Robert Sargis. Reports Clearance Officer. [FR Doc. 2011–15958 Filed 6–24–11; 8:45 am] BILLING CODE 4184–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2011–N–0471] 2011 Scientific Meeting of the National Antimicrobial Resistance Monitoring System; Public Meeting; Request for Comments AGENCY: Food and Drug Administration, HHS. Notice of public meeting; request for comments. ACTION: The Food and Drug Administration (FDA) is announcing a public meeting entitled: ‘‘2011 Scientific Meeting of the National Antimicrobial Resistance Monitoring System.’’ The topic to be discussed is animal and retail sampling methods for the National Antimicrobial Resistance Monitoring System (NARMS). Date and Time: The public meeting will be held on July 20, 2011, from 8 a.m. to 5 p.m. Location: The public meeting will be held at Holiday Inn Select St. Louis Downtown Convention Center Hotel, 811 North 9th Street, St. Louis, MO 63101, 314–421–4000, FAX: 314–421– 5974. Contact Person: Aleta Sindelar, Center for Veterinary Medicine (HFV–3), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240–276– 9004, FAX: 240–276–9001, e-mail: Aleta.Sindelar@fda.hhs.gov. The main purpose of the meeting is to explore ways in which NARMS can improve sampling using current resources. Other topics include: (1) How should NARMS define adequate sampling for resistance trends? (2) What are some additional sources for unbiased food animal samples? (3) What additional information should NARMS collect and report? mstockstill on DSK4VPTVN1PROD with NOTICES SUPPLEMENTARY INFORMATION: VerDate Mar<15>2010 16:51 Jun 24, 2011 Jkt 223001 Requests for Oral Presentations: Interested persons may present data, information, or views, orally or in writing, on the topic of the discussion of the meeting. Written submissions may be made to the contact person on or before July 6, 2011. Oral presentations from the public during the open public comment period will be scheduled between approximately 2 and 3 p.m. on July 20, 2011. Those desiring to make oral presentations should notify the contact person by July 6, 2011, and submit a brief statement of the general nature of information they wish to present and an indication of the approximate time requested to make their presentation. Time allotted for each presentation may be limited. The contact person will inform each speaker of their schedule prior to the meeting. Registration is not required for this meeting, however, early arrival is recommended because seating may be limited. If you need special accommodations due to a disability, please contact Aleta Sindelar (see Contact Person) at least 7 days in advance. Comments: Regardless of attendance at the public meeting, interested persons may submit to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, either electronic or written comments regarding this document. Submit electronic comments to https:// www.regulations.gov. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. The docket will remain open for written or electronic comments for 30 days following the meeting. Agenda: The meeting will address goals and challenges of surveying retail meats and food animals for antimicrobial susceptibility in foodborne bacteria. The agenda for the public meeting will be made available on the Agency’s Web site at https:// www.fda.gov/AnimalVeterinary/ SafetyHealth/AntimicrobialResistance/ NationalAntimicrobial ResistanceMonitoringSystem/ ucm059135.htm. Transcripts: FDA will prepare a meeting transcript and make it available on the Agency’s Web site (see Agenda) after the meeting. FDA anticipates that transcripts will be available approximately 60 business days after PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 the meeting. The transcript will be available for public examination at the Division of Dockets Management (HFA– 305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. A transcript will also be available in either hardcopy or on CD–ROM after submission of a Freedom of Information request. Written requests are to be sent to Division of Freedom of Information (ELEM–1029), Food and Drug Administration, 12420 Parklawn Dr., Element Bldg. Rockville, MD 20857. Dated: June 16, 2011. Leslie Kux, Acting Assistant Commissioner for Policy. [FR Doc. 2011–15982 Filed 6–24–11; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Submission for OMB review; comment request Health Information National Trends Survey 4 (HINTS 4) (NCI) Summary: Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Cancer Institute (NCI), the National Institutes of Health (NIH), has submitted to the Office of Management and Budget (OMB) a request to review and approve the information collection listed below. This proposed information collection was previously published in the Federal Register on April 22, 2011 (76 FR 22714) and allowed 60-days for public comment. One public comment was received on April 23, 2011 which commented on the number of previous surveys and expense. An e-mail response was sent on April 25, 2011, stating, ‘‘Thank you for your comments. We will take your comments into consideration.’’ The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number. Proposed Collection: Title: Health Information National Trends Survey 4 (HINTS 4) (NCI) (OMB 0925–0538, Exp 11/30/2008). Type of Information Collection Request: Reinstatement with Change. Need and Use of Information Collection: HINTS 4 will provide NCI with a comprehensive assessment of the American public’s current access to, and E:\FR\FM\27JNN1.SGM 27JNN1 37357 Federal Register / Vol. 76, No. 123 / Monday, June 27, 2011 / Notices survey will couple knowledge-related questions with inquiries into the communication channels through which understanding is being obtained, and assessment of cancer-related behavior. The Public Health Services Act, Sections 411 (42 U.S.C. 285a) and 412 (42 U.S.C. 285a-1.1 and 285a-1.3), outline the research and information use of, information about cancer across the cancer care continuum from cancer prevention, early detection, diagnosis, treatment, and survivorship. The content of the survey will focus on understanding the degree to which members of the general population understand vital cancer prevention messages. More importantly, this NCI dissemination mission of the NCI which authorizes the collection of this information. Frequency of Response: Once. Affected Public: Individuals. Type of Respondents: U.S. adults (persons aged 18+). The annual reporting burden is documented in the table below. There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report. Cycle 1 ......................................................... Mail survey .................................................. 3,533 1 Cycle 2 ......................................................... Mail survey .................................................. 3,533 1 Cycle 3 ......................................................... Mail survey .................................................. 3,500 1 Cycle 4 ......................................................... Mail survey .................................................. 3,500 1 Total ...................................................... mstockstill on DSK4VPTVN1PROD with NOTICES Data collection cycle Type of respondent ...................................................................... .................... .................... Request for Comments: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, OIRA_submission@omb.eop.gov or by fax to 202–395–6974, Attention: NIH Desk Officer, Office of Management and Budget, at OIRA_submission@omb.eop.gov or by fax to 202–395–6974. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Bradford W. Hesse, PhD, Project Officer, National Cancer Institute, NIH, EPN 4068, 6130 VerDate Mar<15>2010 16:51 Jun 24, 2011 Jkt 223001 Number of respondents Frequency of response Executive Boulevard, MSC 7365, Bethesda, Maryland 20892–7365, or call non-toll free number 301–594–9904 or fax your request to 301–480–2198, or email your request, including your address, to hesseb@mail.nih.gov. Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication. Dated: June 20, 2011. Vivian Horovitch-Kelley, NCI Project Clearance Liaison, National Institutes of Health. [FR Doc. 2011–15994 Filed 6–24–11; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2) notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources, biologics, clinical assays and other developmental programs for potential new therapeutics for the treatment of cancer. The outcome of the evaluation PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 Average time per response minutes/ hour 30/60 (.5) 30/60 (.5) 30/60 (.5) 30/60 (.5) .................... Annual hour burden 1,766.5 1,766.5 1,750 1,750 7,033 will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel, Clinical Assay Development Program (CADP). Date: July 27, 2011. Time: 9 a.m.–4 p.m. Agenda: To review grant applications for the CADP. Place: Bethesda Marriott North Hotel, 5701 Marinelli Road, Bethesda, MD 20852. Contact Person: Dr. Barbara Conley, Executive Secretary, Clinical Assay Development Program (CADP), National Cancer Institute, NIH, 6130 Executive Boulevard, Room 6035A, Bethesda, MD 20892, 301–496–8639, conleyba@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) E:\FR\FM\27JNN1.SGM 27JNN1

Agencies

[Federal Register Volume 76, Number 123 (Monday, June 27, 2011)]
[Notices]
[Pages 37356-37357]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-15994]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Submission for OMB review; comment request Health Information
National Trends Survey 4 (HINTS 4) (NCI)

Summary: Under the provisions of Section 3507(a)(1)(D) of the
Paperwork Reduction Act of 1995, the National Cancer Institute (NCI),
the National Institutes of Health (NIH), has submitted to the Office of
Management and Budget (OMB) a request to review and approve the
information collection listed below. This proposed information
collection was previously published in the Federal Register on April
22, 2011 (76 FR 22714) and allowed 60-days for public comment. One
public comment was received on April 23, 2011 which commented on the
number of previous surveys and expense. An e-mail response was sent on
April 25, 2011, stating, ``Thank you for your comments. We will take
your comments into consideration.'' The purpose of this notice is to
allow an additional 30 days for public comment. The National Institutes
of Health may not conduct or sponsor, and the respondent is not
required to respond to, an information collection that has been
extended, revised, or implemented on or after October 1, 1995, unless
it displays a currently valid OMB control number.
Proposed Collection: Title: Health Information National Trends
Survey 4 (HINTS 4) (NCI) (OMB 0925-0538, Exp 11/30/2008). Type of
Information Collection Request: Reinstatement with Change. Need and Use
of Information Collection: HINTS 4 will provide NCI with a
comprehensive assessment of the American public's current access to,
and

[[Page 37357]]

use of, information about cancer across the cancer care continuum from
cancer prevention, early detection, diagnosis, treatment, and
survivorship. The content of the survey will focus on understanding the
degree to which members of the general population understand vital
cancer prevention messages. More importantly, this NCI survey will
couple knowledge-related questions with inquiries into the
communication channels through which understanding is being obtained,
and assessment of cancer-related behavior. The Public Health Services
Act, Sections 411 (42 U.S.C. 285a) and 412 (42 U.S.C. 285a-1.1 and
285a-1.3), outline the research and information dissemination mission
of the NCI which authorizes the collection of this information.
Frequency of Response: Once. Affected Public: Individuals. Type of
Respondents: U.S. adults (persons aged 18+). The annual reporting
burden is documented in the table below. There are no Capital Costs,
Operating Costs, and/or Maintenance Costs to report.

----------------------------------------------------------------------------------------------------------------
Average
time per Annual
Data collection cycle Type of respondent Number of Frequency response hour
respondents of response minutes/ burden
hour
----------------------------------------------------------------------------------------------------------------
Cycle 1.............................. Mail survey............. 3,533 1 30/60 1,766.5
(.5)
Cycle 2.............................. Mail survey............. 3,533 1 30/60 1,766.5
(.5)
Cycle 3.............................. Mail survey............. 3,500 1 30/60 1,750
(.5)
Cycle 4.............................. Mail survey............. 3,500 1 30/60 1,750
(.5)
--------------------------------------------------------------------------
Total............................ ........................ ........... ........... ........... 7,033
----------------------------------------------------------------------------------------------------------------

Request for Comments: Written comments and/or suggestions from the
public and affected agencies should address one or more of the
following points: (1) Evaluate whether the proposed collection of
information is necessary for the proper performance of the function of
the agency, including whether the information will have practical
utility; (2) Evaluate the accuracy of the agency's estimate of the
burden of the proposed collection of information, including the
validity of the methodology and assumptions used; (3) Enhance the
quality, utility, and clarity of the information to be collected; and
(4) Minimize the burden of the collection of information on those who
are to respond, including the use of appropriate automated, electronic,
mechanical, or other technological collection techniques or other forms
of information technology.
Direct Comments to OMB: Written comments and/or suggestions
regarding the item(s) contained in this notice, especially regarding
the estimated public burden and associated response time, should be
directed to the: Office of Management and Budget, Office of Regulatory
Affairs, OIRA_submission@omb.eop.gov or by fax to 202-395-6974,
Attention: NIH Desk Officer, Office of Management and Budget, at OIRA_submission@omb.eop.gov or by fax to 202-395-6974. To request more
information on the proposed project or to obtain a copy of the data
collection plans and instruments, contact Bradford W. Hesse, PhD,
Project Officer, National Cancer Institute, NIH, EPN 4068, 6130
Executive Boulevard, MSC 7365, Bethesda, Maryland 20892-7365, or call
non-toll free number 301-594-9904 or fax your request to 301-480-2198,
or e-mail your request, including your address, to hesseb@mail.nih.gov.
Comments Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 30 days
of the date of this publication.

Dated: June 20, 2011.
Vivian Horovitch-Kelley,
NCI Project Clearance Liaison, National Institutes of Health.
[FR Doc. 2011-15994 Filed 6-24-11; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.